Icosapent/Gamolenic acid/Lithium gamolenate

N/A

Report date: 2023/04/23 15:22:47

Base Information

Drug NameIcosapent/Gamolenic acid/Lithium gamolenate
Drug Alias NameEPA+GLA+Lithium gamma-linoleateIcosapent+Gamolenic acid+Lithium gamolenateEF-12
ClassificationSmall molecules
Mechanisms of ActionThromboxane A2 synthase inhibitorsCyclooxygenases stimulants
TargetsThromboxane A2 synthaseCyclooxygenases
Therapy Area/IndicationsCoronary RestenosisCoronary Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Eicosapentaenoic acidLithium gamolenateGamolenic acid
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesScotia
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesScotia
Active IndicationsN/A
Inactive IndicationsCoronary RestenosisCoronary Disease

Other Information

ATC CodeN/A
Related LinksN/A